TW200526227A - Methods of treating vasomotor symptoms - Google Patents

Methods of treating vasomotor symptoms Download PDF

Info

Publication number: TW200526227A
Authority: TW; Taiwan
Prior art keywords: ethyl; cyclohexanol; pharmaceutically acceptable; reuptake inhibitor; hexahydropyridyl
Prior art date: 2003-10-14

Application number

TW093130953A

Other languages

English (en)

Chinese (zh)

Inventor

Darlene Coleman Deecher

Chad Edward Beyer

Liza Leventhal

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-14

Filing date

2004-10-13

Publication date

2005-08-16

2003-10-14 Priority claimed from US10/685,812 external-priority patent/US20040152710A1/en

2004-10-12 Priority claimed from US10/962,897 external-priority patent/US20050130987A1/en

2004-10-13 Application filed by Wyeth Corp filed Critical Wyeth Corp

2005-08-16 Publication of TW200526227A publication Critical patent/TW200526227A/zh

Links

238000000034 method Methods 0.000 title claims abstract description 55
208000024891 symptom Diseases 0.000 title claims abstract description 41
230000001457 vasomotor Effects 0.000 title claims abstract description 35
239000002767 noradrenalin uptake inhibitor Substances 0.000 claims abstract description 90
229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims abstract description 90
150000001875 compounds Chemical class 0.000 claims abstract description 74
239000003772 serotonin uptake inhibitor Substances 0.000 claims abstract description 59
230000009977 dual effect Effects 0.000 claims abstract description 18
239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims abstract description 6
230000001919 adrenal effect Effects 0.000 claims description 106
150000003839 salts Chemical class 0.000 claims description 77
229940044551 receptor antagonist Drugs 0.000 claims description 68
239000002464 receptor antagonist Substances 0.000 claims description 68
229940126570 serotonin reuptake inhibitor Drugs 0.000 claims description 60
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 54
239000003112 inhibitor Substances 0.000 claims description 51
239000000203 mixture Substances 0.000 claims description 50
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims description 36
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 36
230000000694 effects Effects 0.000 claims description 34
239000008194 pharmaceutical composition Substances 0.000 claims description 33
238000011010 flushing procedure Methods 0.000 claims description 31
-1 1-ethyl-2-imidazolyl Chemical group 0.000 claims description 30
230000009245 menopause Effects 0.000 claims description 25
239000003814 drug Substances 0.000 claims description 23
239000004480 active ingredient Substances 0.000 claims description 21
239000000013 adrenergic uptake inhibitor Substances 0.000 claims description 21
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 18
230000013283 epinephrine uptake Effects 0.000 claims description 17
239000003937 drug carrier Substances 0.000 claims description 15
239000004615 ingredient Substances 0.000 claims description 14
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 11
230000009103 reabsorption Effects 0.000 claims description 11
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 9
229940076279 serotonin Drugs 0.000 claims description 9
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
235000019098 Sedum telephium Nutrition 0.000 claims description 8
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
206010027304 Menopausal symptoms Diseases 0.000 claims description 7
229960003914 desipramine Drugs 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 6
229960004688 venlafaxine Drugs 0.000 claims description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 4
YUTGLCAFRPAGFA-UHFFFAOYSA-N 1-[2-(dimethylamino)-1-[3-(trifluoromethyl)phenyl]ethyl]cyclohexan-1-ol Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=CC(C(F)(F)F)=C1 YUTGLCAFRPAGFA-UHFFFAOYSA-N 0.000 claims description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
210000004100 adrenal gland Anatomy 0.000 claims description 4
VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims description 4
229960002430 atomoxetine Drugs 0.000 claims description 4
ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 4
229960005426 doxepin Drugs 0.000 claims description 4
229960002866 duloxetine Drugs 0.000 claims description 4
229960004090 maprotiline Drugs 0.000 claims description 4
QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims description 4
ITJNARMNRKSWTA-UHFFFAOYSA-N nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 claims description 4
229950004211 nisoxetine Drugs 0.000 claims description 4
229960003770 reboxetine Drugs 0.000 claims description 4
CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims description 4
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 4
FDZUJJJSDXJJMX-UHFFFAOYSA-N C(C)N1C(=NC=C1)C1(COC2=C(O1)C=CC=C2)C Chemical group C(C)N1C(=NC=C1)C1(COC2=C(O1)C=CC=C2)C FDZUJJJSDXJJMX-UHFFFAOYSA-N 0.000 claims description 3
VXJUGMJPSSEBDJ-UHFFFAOYSA-N CC1CCN(CC1)CC(C2=CC(=CC=C2)C(F)(F)F)C3(CCCCC3)O Chemical compound CC1CCN(CC1)CC(C2=CC(=CC=C2)C(F)(F)F)C3(CCCCC3)O VXJUGMJPSSEBDJ-UHFFFAOYSA-N 0.000 claims description 3
FCCRUSRVFBKOAK-UHFFFAOYSA-N CC1CCN(CC1)CC(C2=CC(=CC=C2)Cl)C3(CCCCC3)O Chemical compound CC1CCN(CC1)CC(C2=CC(=CC=C2)Cl)C3(CCCCC3)O FCCRUSRVFBKOAK-UHFFFAOYSA-N 0.000 claims description 3
KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 claims description 3
XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 claims description 3
GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims description 2
ZUFCXVFSSJFSOT-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-(dimethylamino)ethyl]cyclohexan-1-ol Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=CC(Cl)=C1 ZUFCXVFSSJFSOT-UHFFFAOYSA-N 0.000 claims description 2
UXABARREKCJULM-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-ethylimidazole Chemical compound CCN1C=CN=C1CC1OC2=CC=CC=C2OC1 UXABARREKCJULM-UHFFFAOYSA-N 0.000 claims description 2
SAJKHRHHDGSJEZ-UHFFFAOYSA-N 2-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-4,4-dimethylisoquinoline-1,3-dione;dihydrochloride Chemical compound Cl.Cl.COC1=CC=CC=C1N1CCN(CCN2C(C(C)(C)C3=CC=CC=C3C2=O)=O)CC1 SAJKHRHHDGSJEZ-UHFFFAOYSA-N 0.000 claims description 2
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 2
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 2
229960002519 amoxapine Drugs 0.000 claims description 2
QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims description 2
229950008608 imiloxan Drugs 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
229960000600 milnacipran Drugs 0.000 claims description 2
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 6
JDXKNIFBLNEMJI-UHFFFAOYSA-N OC1(CCCCC1)C(CN1CCC(CC2=CC=CC=C2)CC1)C(C=C1)=CC=C1F Chemical compound OC1(CCCCC1)C(CN1CCC(CC2=CC=CC=C2)CC1)C(C=C1)=CC=C1F JDXKNIFBLNEMJI-UHFFFAOYSA-N 0.000 claims 4
241000220287 Sedum rubrotinctum Species 0.000 claims 2
229960001623 desvenlafaxine Drugs 0.000 claims 2
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 claims 2
UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims 1
XZVLBOBOAIDHCX-UHFFFAOYSA-N 1-[1-(3-methoxyphenyl)-2-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]ethyl]cyclopentan-1-ol Chemical compound COC=1C=C(C=CC1)C(CN1CCC(CC1)C1=CC(=CC=C1)C(F)(F)F)C1(CCCC1)O XZVLBOBOAIDHCX-UHFFFAOYSA-N 0.000 claims 1
ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 claims 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
KCERENODDFXHOL-UHFFFAOYSA-N COC1=CC=CC(=C1)C(CN2CCC(CC2)C3=CC(=CC=C3)C(F)(F)F)C4(CCCCC4)O Chemical compound COC1=CC=CC(=C1)C(CN2CCC(CC2)C3=CC(=CC=C3)C(F)(F)F)C4(CCCCC4)O KCERENODDFXHOL-UHFFFAOYSA-N 0.000 claims 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
150000001335 aliphatic alkanes Chemical class 0.000 claims 1
UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 1
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical group ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims 1
239000003599 detergent Substances 0.000 claims 1
125000001207 fluorophenyl group Chemical group 0.000 claims 1
229960001915 hexamidine Drugs 0.000 claims 1
210000003734 kidney Anatomy 0.000 claims 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims 1
210000002966 serum Anatomy 0.000 claims 1
239000005557 antagonist Substances 0.000 abstract description 32
238000011282 treatment Methods 0.000 abstract description 22
230000001800 adrenalinergic effect Effects 0.000 abstract description 4
102100030140 Thiosulfate:glutathione sulfurtransferase Human genes 0.000 description 25
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 20
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 19
241000700159 Rattus Species 0.000 description 18
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 18
229960004127 naloxone Drugs 0.000 description 18
241001465754 Metazoa Species 0.000 description 14
108020003175 receptors Proteins 0.000 description 12
102000005962 receptors Human genes 0.000 description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
238000001690 micro-dialysis Methods 0.000 description 11
229940011871 estrogen Drugs 0.000 description 10
239000000262 estrogen Substances 0.000 description 10
239000007788 liquid Substances 0.000 description 10
229960005181 morphine Drugs 0.000 description 10
229940079593 drug Drugs 0.000 description 9
239000000523 sample Substances 0.000 description 9
239000000969 carrier Substances 0.000 description 8
210000003169 central nervous system Anatomy 0.000 description 8
208000035475 disorder Diseases 0.000 description 8
230000002401 inhibitory effect Effects 0.000 description 8
238000005259 measurement Methods 0.000 description 8
229920000609 methyl cellulose Polymers 0.000 description 8
239000001923 methylcellulose Substances 0.000 description 8
235000010981 methylcellulose Nutrition 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 7
238000004128 high performance liquid chromatography Methods 0.000 description 7
210000003016 hypothalamus Anatomy 0.000 description 7
210000001428 peripheral nervous system Anatomy 0.000 description 7
229920000136 polysorbate Polymers 0.000 description 7
230000004044 response Effects 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
244000072882 Sedum telephium Species 0.000 description 6
230000001419 dependent effect Effects 0.000 description 6
229940088597 hormone Drugs 0.000 description 6
239000005556 hormone Substances 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
239000000651 prodrug Substances 0.000 description 6
229940002612 prodrug Drugs 0.000 description 6
230000035900 sweating Effects 0.000 description 6
238000012360 testing method Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
206010006187 Breast cancer Diseases 0.000 description 5
208000026310 Breast neoplasm Diseases 0.000 description 5
108010078791 Carrier Proteins Proteins 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
230000009102 absorption Effects 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
238000007429 general method Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
206010022437 insomnia Diseases 0.000 description 5
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 5
239000000843 powder Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
238000007920 subcutaneous administration Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
241000282412 Homo Species 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
230000008859 change Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
229940090044 injection Drugs 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
239000007937 lozenge Substances 0.000 description 4
230000003821 menstrual periods Effects 0.000 description 4
206010029410 night sweats Diseases 0.000 description 4
230000036565 night sweats Effects 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
150000003384 small molecules Chemical class 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 3
208000029061 Temperature regulation disease Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229960002896 clonidine Drugs 0.000 description 3
230000007423 decrease Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
230000003054 hormonal effect Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000009806 oophorectomy Methods 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
230000035479 physiological effects, processes and functions Effects 0.000 description 3
230000003449 preventive effect Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000028016 temperature homeostasis Effects 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
206010060800 Hot flush Diseases 0.000 description 2
208000008454 Hyperhidrosis Diseases 0.000 description 2
206010022998 Irritability Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 2
108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000002730 additional effect Effects 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
239000003098 androgen Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
210000000133 brain stem Anatomy 0.000 description 2
150000001722 carbon compounds Chemical class 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000007906 compression Methods 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
229940012356 eye drops Drugs 0.000 description 2
206010016256 fatigue Diseases 0.000 description 2
230000035558 fertility Effects 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
239000003163 gonadal steroid hormone Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
229960003132 halothane Drugs 0.000 description 2
230000009931 harmful effect Effects 0.000 description 2
238000001794 hormone therapy Methods 0.000 description 2
238000002513 implantation Methods 0.000 description 2
230000036512 infertility Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
238000007915 intraurethral administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000000116 mitigating effect Effects 0.000 description 2
230000001722 neurochemical effect Effects 0.000 description 2
239000002674 ointment Substances 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
238000002638 palliative care Methods 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
230000002265 prevention Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
229940035613 prozac Drugs 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
238000011552 rat model Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
239000008174 sterile solution Substances 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
230000001331 thermoregulatory effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 2
229960000317 yohimbine Drugs 0.000 description 2
AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 2
229940124629 β-receptor antagonist Drugs 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
RHBGITBPARBDPH-UHFFFAOYSA-N (2E,4E)-5-(3,4-methylenedioxyphenyl)-2,4-pentadienoic acid Natural products OC(=O)C=CC=CC1=CC=C2OCOC2=C1 RHBGITBPARBDPH-UHFFFAOYSA-N 0.000 description 1
HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
RHBGITBPARBDPH-ZPUQHVIOSA-N (E,E)-piperic acid Chemical compound OC(=O)\C=C\C=C\C1=CC=C2OCOC2=C1 RHBGITBPARBDPH-ZPUQHVIOSA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
ZWAMJENZBDVVDH-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-piperidin-1-ylethyl]cyclohexan-1-ol Chemical compound C1CCCCN1CC(C=1C=C(Cl)C=CC=1)C1(O)CCCCC1 ZWAMJENZBDVVDH-UHFFFAOYSA-N 0.000 description 1
229940015297 1-octanesulfonic acid Drugs 0.000 description 1
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
229920002972 Acrylic fiber Polymers 0.000 description 1
101150078577 Adora2b gene Proteins 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
235000011297 Brassica napobrassica Nutrition 0.000 description 1
240000002791 Brassica napus Species 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241001269524 Dura Species 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000033830 Hot Flashes Diseases 0.000 description 1
206010058359 Hypogonadism Diseases 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010029216 Nervousness Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
206010033165 Ovarian failure Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241000233805 Phoenix Species 0.000 description 1
208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
229910021607 Silver chloride Inorganic materials 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000862969 Stella Species 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
208000006593 Urologic Neoplasms Diseases 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000008649 adaptation response Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
229960004365 benzoic acid Drugs 0.000 description 1
230000027455 binding Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000009956 central mechanism Effects 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000007357 depressive behavior Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
150000004656 dimethylamines Chemical class 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000009510 drug design Methods 0.000 description 1
238000009509 drug development Methods 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
230000001834 epinephrinelike Effects 0.000 description 1
238000009164 estrogen replacement therapy Methods 0.000 description 1
230000012173 estrus Effects 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
229960002464 fluoxetine Drugs 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
229920000591 gum Polymers 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical class C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 1
238000002657 hormone replacement therapy Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000009802 hysterectomy Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
229960000448 lactic acid Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229940099690 malic acid Drugs 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000008897 memory decline Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
238000001471 micro-filtration Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
208000008013 morphine dependence Diseases 0.000 description 1
WUOSYUHCXLQPQJ-UHFFFAOYSA-N n-(3-chlorophenyl)-n-methylacetamide Chemical compound CC(=O)N(C)C1=CC=CC(Cl)=C1 WUOSYUHCXLQPQJ-UHFFFAOYSA-N 0.000 description 1
229940024844 naloxone injection Drugs 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
238000010606 normalization Methods 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003401 opiate antagonist Substances 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
201000004535 ovarian dysfunction Diseases 0.000 description 1
231100000539 ovarian failure Toxicity 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
229940055726 pantothenic acid Drugs 0.000 description 1
235000019161 pantothenic acid Nutrition 0.000 description 1
230000001936 parietal effect Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
230000009955 peripheral mechanism Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
235000003784 poor nutrition Nutrition 0.000 description 1
230000016833 positive regulation of signal transduction Effects 0.000 description 1
238000013105 post hoc analysis Methods 0.000 description 1
238000010149 post-hoc-test Methods 0.000 description 1
230000002028 premature Effects 0.000 description 1
206010036601 premature menopause Diseases 0.000 description 1
210000003814 preoptic area Anatomy 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000019633 pungent taste Nutrition 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
239000013074 reference sample Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229910052702 rhenium Inorganic materials 0.000 description 1
WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
238000005070 sampling Methods 0.000 description 1
239000000565 sealant Substances 0.000 description 1
239000013049 sediment Substances 0.000 description 1
HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
208000022925 sleep disturbance Diseases 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012353 t test Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
239000004034 viscosity adjusting agent Substances 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

TW093130953A 2003-10-14 2004-10-13 Methods of treating vasomotor symptoms TW200526227A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US51089703P	2003-10-14	2003-10-14
US10/685,812 US20040152710A1 (en)	2002-10-15	2003-10-14	Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
PCT/US2003/032759 WO2004035058A1 (en)	2002-10-15	2003-10-15	Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US10/962,897 US20050130987A1 (en)	2003-10-14	2004-10-12	Methods of treating vasomotor symptoms

Publications (1)

Publication Number	Publication Date
TW200526227A true TW200526227A (en)	2005-08-16

Family

ID=36566007

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW093130953A TW200526227A (en)	2003-10-14	2004-10-13	Methods of treating vasomotor symptoms

Country Status (4)

Country	Link
JP (1)	JP2007515395A (pt)
BR (1)	BRPI0415280A (pt)
CA (1)	CA2539757A1 (pt)
TW (1)	TW200526227A (pt)

2004
- 2004-10-13 CA CA002539757A patent/CA2539757A1/en not_active Abandoned
- 2004-10-13 TW TW093130953A patent/TW200526227A/zh unknown
- 2004-10-13 JP JP2006535623A patent/JP2007515395A/ja not_active Withdrawn
- 2004-10-13 BR BRPI0415280-8A patent/BRPI0415280A/pt not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2539757A1 (en)	2005-04-28
JP2007515395A (ja)	2007-06-14
BRPI0415280A (pt)	2006-12-19

Publication	Publication Date	Title
US20080227850A1 (en)	2008-09-18	Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
RU2340333C2 (ru)	2008-12-10	Агонизм 5нт2a -рецептора для лечения нарушения функции терморегуляции
TW200413001A (en)	2004-08-01	Use for norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en)	2004-09-16	Novel method of treating vasomotor symptoms
JP2008507551A (ja)	2008-03-13	神経系疾患および病態の治療方法
KR20070034129A (ko)	2007-03-27	신경계 질환 및 장애의 치료 방법
TW200526227A (en)	2005-08-16	Methods of treating vasomotor symptoms
US20050130987A1 (en)	2005-06-16	Methods of treating vasomotor symptoms
KR20070034126A (ko)	2007-03-27	신경계 질환 및 장애의 치료 방법
CN101189043A (zh)	2008-05-28	肾上腺素能α2B拮抗剂用于治疗血管舒缩症状的应用
MXPA06003866A (es)	2006-07-03	Metodos de tratamiento de sintomas vasomotores.
CN1705475A (zh)	2005-12-07	通过具有去甲肾上腺素重摄取抑制剂活性和5－ht2a拮抗活性的化合物治疗血管舒缩症的方法
CN1705484A (zh)	2005-12-07	去甲肾上腺素重摄取调节剂用于预防和治疗血管舒缩症的用途